Palatin Technologies, Inc.
(NYSE Amex Equities : PTN)

( )
PTN After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. 1.59%154.960.0%$1509.75m
NVAXNovavax, Inc. 2.55%79.1878.2%$568.86m
AMGNAmgen, Inc. -1.11%222.541.4%$546.33m
GILDGilead Sciences, Inc. -2.18%67.341.0%$534.08m
BIIBBiogen, Inc. -1.22%219.601.8%$496.23m
BNTXBioNTech SE 2.69%160.700.0%$493.59m
REGNRegeneron Pharmaceuticals, Inc. 0.34%605.252.7%$434.03m
ILMNIllumina, Inc. -3.77%331.783.3%$370.86m
VRTXVertex Pharmaceuticals, Inc. -0.23%226.581.9%$358.72m
SNSSSunesis Pharmaceuticals, Inc. -4.71%2.630.7%$183.85m
EXASEXACT Sciences Corp. -0.42%68.8917.9%$173.71m
INCYIncyte Corp. -0.85%73.522.4%$141.06m
ARNAArena Pharmaceuticals, Inc. -0.29%89.6313.7%$135.69m
BMRNBioMarin Pharmaceutical, Inc. -1.37%83.704.2%$108.53m
CRSPCRISPR Therapeutics AG -1.12%61.840.6%$107.20m

Company Profile

Palatin Technologies, Inc. is a biopharmaceutical company, which engages in the development of medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. Its primary product candidate is marketed under the Vyleesi brand, the trade name for bremelanotide, a peptide melanocortin receptor 4 agonist for the treatment of premenopausal women with acquired, generalized, hypoactive sexual desire disorder (HSDD). The company was founded by Carl Spana and John K. A. Prendergast on November 21, 1986 and is headquartered in Cranbury, NJ.